Pfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2024

  1. Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016–2019

    Infectious Diseases and Therapy

2023

  1. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: A pooled analysis from the Phase 3 clinical trial programme

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 11, pp. 2672-2682

  2. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia

    European Respiratory Review, Vol. 32, Núm. 170

2022

  1. Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System

    ClinicoEconomics and Outcomes Research, Vol. 14, pp. 149-161

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2015

  1. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma

    Molecular Cancer Therapeutics, Vol. 14, Núm. 7, pp. 1548-1558

2008

  1. The efficacy and safety of tigecycline for the treatment of complicated intra-adominal infections - The European experience

    Journal of Chemotherapy, Vol. 20, Núm. SUPPL. 1, pp. 12-19

1991

  1. Expression and Characterization of a Basic Fibroblast Growth Factor‐Saporin Fusion Protein in Escherichia coli

    Annals of the New York Academy of Sciences, Vol. 638, Núm. 1, pp. 434-437